Canada markets closed

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.0000-0.2000 (-3.85%)
At close: 04:00PM EST
5.1000 +0.10 (+2.00%)
After hours: 07:54PM EST

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees188

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.Co-Founder, Pres, CEO & Director873.68kN/A1967
Mr. Erin E. Jones M.S.Chief Operating Officer537.38kN/A1972
Ms. Vassiliki EconomidesExec. VP & CFON/AN/A1980
Mr. James ChoChief Accounting OfficerN/AN/AN/A
Mr. Rahsaan W. Thompson J.D.Exec. VP & Gen. CounselN/AN/A1971
Ms. Stacy ProctorSr. VP & Head of PeopleN/AN/AN/A
Dr. Matthew HawrylukExec. VP & Chief Bus. OfficerN/AN/A1978
Dr. Karin JoossHead of R&DN/AN/A1965
Mr. Vijay Yabannavar Ph.D.Exec. VP & Chief Technical Devel. OfficerN/AN/A1962
Mr. Alan C. Mendelson J.D.Sec.N/AN/A1950
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.